These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 23475638)

  • 1. Treating iron overload in patients with non-transfusion-dependent thalassemia.
    Taher AT; Viprakasit V; Musallam KM; Cappellini MD
    Am J Hematol; 2013 May; 88(5):409-15. PubMed ID: 23475638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
    Taher AT; Temraz S; Cappellini MD
    Expert Rev Hematol; 2013 Oct; 6(5):495-509. PubMed ID: 24083402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How I treat non-transfusion-dependent β-thalassemia.
    Saliba AN; Musallam KM; Taher AT
    Blood; 2023 Sep; 142(11):949-960. PubMed ID: 37478396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morbidities in non-transfusion-dependent thalassemia.
    Saliba AN; Taher AT
    Ann N Y Acad Sci; 2016 Mar; 1368(1):82-94. PubMed ID: 27186941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.
    Taher AT; Musallam KM; Viprakasit V; Porter JB; Cappellini MD
    Blood Cells Mol Dis; 2014; 52(2-3):88-90. PubMed ID: 24041597
    [No Abstract]   [Full Text] [Related]  

  • 6. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective.
    Musallam KM; Cappellini MD; Wood JC; Taher AT
    Blood Rev; 2012 Apr; 26 Suppl 1():S16-9. PubMed ID: 22631036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of non-transfusion-dependent β-thalassemia (NTDT): The next 5 years.
    Musallam KM; Rivella S; Taher AT
    Am J Hematol; 2021 Mar; 96(3):E57-E59. PubMed ID: 33219704
    [No Abstract]   [Full Text] [Related]  

  • 8. Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.
    Ricchi P; Marsella M
    Drug Des Devel Ther; 2015; 9():6475-82. PubMed ID: 26719673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron overload in thalassemia: different organs at different rates.
    Taher AT; Saliba AN
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):265-271. PubMed ID: 29222265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series.
    Pinto VM; Forni GL
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron Chelation Therapy as a Modality of Management.
    Aydinok Y
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):261-275. PubMed ID: 29458731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current approach to iron chelation in children.
    Aydinok Y; Kattamis A; Viprakasit V
    Br J Haematol; 2014 Jun; 165(6):745-55. PubMed ID: 24646011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
    Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.
    Bou-Fakhredin R; Bazarbachi AH; Chaya B; Sleiman J; Cappellini MD; Taher AT
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management.
    Vichinsky E
    Curr Med Res Opin; 2016; 32(1):191-204. PubMed ID: 26479125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Transfusion-Dependent Thalassemia: A Panoramic Review.
    Shash H
    Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial.
    Elalfy MS; Adly A; Awad H; Tarif Salam M; Berdoukas V; Tricta F
    Am J Hematol; 2018 Feb; 93(2):262-268. PubMed ID: 29119631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of non-transfusion-dependent thalassemia: a practical guide.
    Taher AT; Cappellini MD
    Drugs; 2014 Oct; 74(15):1719-29. PubMed ID: 25255924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiological and clinical aspects of iron chelation therapy in MDS.
    Gattermann N
    Curr Pharm Des; 2012; 18(22):3222-34. PubMed ID: 22571702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.